Intra-articular injection of the selective cyclooxygenase-2 inhibitor meloxicam (Mobic) reduces experimental osteoarthritis and nociception in rats

Osteoarthritis and Cartilage

Volumn 21, Issue 12, 2013, Pages 1976-1986

  Wen, Z H ^a   Tang, C C ^b   Chang, Y C ^a   Huang, S Y ^a   Chen, C H ^a   Wu, S C ^a   Hsieh, S P ^c   Hsieh, C S ^d   Wang, K Y ^c   Lin, S Y ^c   Lee, H L ^e   Lee, C H ^f   Kuo, H C ^g   Chen, W F ^h   Jean, Y H ^c  

^a NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^b National Pintung University of Education   (Taiwan)

^c PINGTUNG CHRISTIAN HOSPITAL   (Taiwan)

^d Heng Chun Christian Hospital   (Taiwan)

^e TAJEN UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g Chao Liao Junior High School   (Taiwan)

^h CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Anterior cruciate ligament; MAPK; Meloxicam (Mobic); Nociception; Osteoarthritis

Indexed keywords

MELOXICAM; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTERIOR CRUCIATE LIGAMENT TRANSECTION; ARTHROTOMY; ARTICLE; ARTICULAR CARTILAGE; BODY WEIGHT; BONE EROSION; CARTILAGE DEGENERATION; CONTROLLED STUDY; ENZYME ACTIVITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KNEE LIGAMENT SURGERY; MALE; MECHANICAL ALLODYNIA; NOCICEPTION; NONHUMAN; OSTEOARTHRITIS; OSTEOPHYTE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYNOVITIS; SYNOVIUM; ULCEROGENESIS; WEIGHT BEARING;

ANTERIOR CRUCIATE LIGAMENT; MAPK; MELOXICAM (MOBIC); NOCICEPTION; OSTEOARTHRITIS;

ANIMALS; ANTERIOR CRUCIATE LIGAMENT; ARTHRITIS, EXPERIMENTAL; CARTILAGE, ARTICULAR; CHONDROCYTES; CYCLOOXYGENASE 2 INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; INJECTIONS, INTRA-ARTICULAR; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; NOCICEPTION; OSTEOARTHRITIS, KNEE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, WISTAR; SYNOVIAL MEMBRANE; THIAZINES; THIAZOLES;

EID: 84888861909     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2013.09.005     Document Type: Article

References (51)

1. Pelletier J.P., Martel-Pelletier J., Abramson S.B. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001, 44:1237-1247.
2. Türck D., Busch U., Heinzel G., Narjes H. Clinical pharmacokinetics of meloxicam. Arzneimittelforschung 1997, 47:253-258.
3. Engelhardt G. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Br J Rheumatol 1996 Apr, 35(Suppl 1):4-12.
4. Cryer B., Dubois A. The advent of highly selective inhibitors of cyclooxygenase-2, a review. Prostaglandins Other Lipid Mediators 1998, 56:341-361.
5. Patrignani P., Panara M.R., Sciulli M.G., Santini G., Renda G., Ptrono C. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. JPhysiol Pharmacol 1997, 48:623-631.
6. Ahmed M., Khanna D., Furst D.E. Meloxicam in rheumatoid arthritis. Expert Opin Drug Metab Toxicol 2005, 1:739-751.
7. Valat J.P., Accardo S., Reginster J.Y., Wouters M., Hettich M., Lieu P.L. Acomparison of the efficacy and tolerability of meloxicam and diclofenac in the treatment of patients with osteoarthritis of the lumbar spine. Inflamm Res 2001, 50(Suppl 1):S30-S34.
8. Laird J.M., Herrero J.F., Garcia-de-la-Rubia P., Cervero F. Analgesic activity of the novel COX-2 preferring NSAID, meloxicam in mono-arthritic rats: central and peripheral components. Inflamm Res 1997, 46:203-210.
9. Engelhardt G., Homma D., Schlegel K., Utzmann R., Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995, 44:423-433.
10. Jones M.D., Tran C.W., Li G., Maksymowych W.P., Zernicke R.F., Doschak M.R. Invivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat. Arthritis Rheum 2010, 62(9):2726-2735.
11. de Grauw J.C., van de Lest C.H., Brama P.A., Rambags B.P., van Weeren P.R. Invivo effects of meloxicam on inflammatory mediators, MMP activity and cartilage biomarkers in equine joints with acute synovitis. Equine Vet J 2009, 41:693-699.
12. Dudhgaonkar S.P., Tandan S.K., Kumar D., Arunadevi R., Prakash V.R. Synergistic interaction between meloxicam and aminoguanidine in formalin-induced nociception in mice. Eur J Pain 2008, 12:321-328.
13. Brown K.K., Heitmeyer S.A., Hookfin E.B., Hsieh L., Buchalova M., Taiwo Y.O., et al. P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. JInflamm 2008, 5:22-29.
14. Ji R.R., Woolf C.J. Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiol Dis 2001, 8:1-10.
15. Namdari S., Wei L., Moore D., Chen Q. Reduced limb length and worsened osteoarthritis in adult mice after genetic inhibition of p38 MAP Kinase activity in cartilage. Arthritis Rheum 2008, 11:3520-3529.
16. Prasadam I., van Gennip S., Friis T., Shi W., Crawford, Xiao Y. ERK1/2 and p38 in the regulation of hypertrophic changes of normal articular cartilage chondrocytes induced by osteoarthritic subchondral osteoblasts. Arthritis Rheum 2010, 62(5):1349-1360.
17. Clancy R., Rediske J., Koehne C., Stoyanovsky D., Amin A., Attur M., et al. Activation of stress-activated protein kinase in osteoarthritic cartilage: evidence for nitric oxide dependence. Osteoarthritis Cartilage 2001, 9:294-299.
18. Fan Z., Soder S., Oehler S., Fundel K., Aigner T. Activation of interleukin-1 signaling cascades in normal and osteoarthritic articular cartilage. Am J Pathol 2007, 171:938-946.
19. Giovannini M.G. The role of the extracellular signal-regulated kinase pathway in memory encoding. Rev Neurosci 2006, 17(6):619-634.
20. Boileau C., Martel-Pelletier J., Brunet J., Schrier D., Flory C., Boily M., et al. PD-0200347, an alpha 2 delta ligand of the voltage gated calcium channel, inhibits invivo activation of the Erk1/2 pathway in osteoarthritic chondrocytes: a PKC alpha dependent effect. Ann Rheum Dis 2006, 65:573-580.
21. Damjanov N., Kauffman R.S., Spencer-Green G.T. Efficacy, pharmacodynamics, and safety of CX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis. Arthritis Rheum 2009, 60:1232-1241.
22. Wen Z.H., Tang C.C., Chang Y.C., Huang S.Y., Hsieh S.P., Lee C.H., et al. Glucosamine sulfate reduces experimental osteoarthritis and nociception in rats: association with changes of mitogen-activated protein kinase in chondrocytes. Osteoarthritis Cartilage 2010, 18(9):1192-1202.
23. Jean Y.H., Wen Z.H., Chang Y.C., Huang G.S., Lee H.S., Hsieh S.P., et al. Increased concentrations of neuro-excitatory amino acids in rat anterior cruciate ligament-transected knee joint dialysates: a microdialysis study. JOrthop Res 2005, 23:569-575.
24. Jean Y.H., Wen Z.H., Chang Y.C., Hsieh S.P., Tang C.C., Wang Y.H., et al. Intra-articular injection of cyclooxygenase-2 inhibitor parecoxib attenuates osteoarthritis progression in anterior cruciate ligament-transection knee in rats: role of excitatory amino acids. Osteoarthritis Cartilage 2007, 15:638-645.
25. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. JNeurosci Methods 1994, 53:55-63.
26. Fernihough J., Gentry C., Malcangio M., Fox A., Rediske J., Pellas T., et al. Pain related behaviour in two models of osteoarthritis in the rat knee. Pain 2004, 112:83-93.
27. Pomonis J.D., Boulet J.M., Gottshall S.L., Phillips S., Sellers R., Bunton T., et al. Development and pharmacological characterization of a rat model of osteoarthritis pain. Pain 2005, 114(3):339-346.
28. Kiviranta I., Jurvelin J., Tammi M., Saamanen A.M., Helminen H.J. Microspectrophotometric quantitation of glycosaminoglycans in articular cartilage sections stained with Safranin O. Histochemistry 1985, 82:249-255.
29. Janusz M.J., Bendele A.M., Brown K.K., Taiwo Y.O., Hsieh L., Heitmeyer S.A. Induction of osteoarthritis in the rat by surgical tear of the meniscus: inhibition of joint damage by a matrix metalloproteinase inhibitor. Osteoarthritis Cartilage 2002, 10:785-791.
30. Pritzker K.P., Gay S., Jimenez S.A., Ostergaard K., Pelletier J.P., Revell P.A., et al. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage 2006, 14:13-29.
31. Yoshimi T., Kikuchi T., Obrara T., Yamaguchi T., Sakakibara Y., Itoh H., et al. Effects of high-molecular-weight sodium hyaluronate on experimental osteoarthritis induced by the resection of rabbit cruciate ligament. Clin Orthop 1994, 298:296-304.
32. 4) reduces experimental osteoarthritis and nociception: association with attenuation of N-methyl-D-aspartate (NMDA) receptor subunit 1 phosphorylation and apoptosis in rat chondrocytes. Osteoarthritis Cartilage 2009, 17:1485-1493.
33. Jean Y.H., Wen Z.H., Chang Y.C., Hsieh S.P., Tang C.C., Lin J.D., et al. Increase in excitatory amino acid concentration and transporters expression in osteoarthritic knees of anterior cruciate ligament transected rabbits. Osteoarthritis Cartilage 2008, 16:1442-1449.
34. Rainsford K.D., Ying C., Smith F.C. Effects of meloxicam, compared with other NSAIDs, on cartilage proteoglycan metabolism, synovial prostaglandin E2, and production of interleukin 1, 6 and 8, in human and porcine explants in organ culture. JPharm Pharmacol 1997, 49:991-998.
35. Blot L., Marcelis A., Devogelaer J.P., Manicourt D.H. Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol 2000, 131(7):1413-1421.
36. Canadian Pharmacists Association Compendium of Pharmaceutical and Specialties. The Canadian Drug Reference for Health Professionals 2003, Canadian Pharmacists Association, Ottawa.
37. Carroll G.L., Howe L.B., Peterson K.D. Analgesic efficacy of preoperative administration of meloxicam or butorphanol in onychectomized cats. Am Vet Med Assoc 2005, 226:913-919.
38. Roughan J.V., Flecknell P.A. Evaluation of a short duration behaviour-based post-operative pain scoring system in rats. Eur J Pain 2003, 7:397-406.
39. Richardson C.A., Niel L., Leach M.C., Flecknell P.A. Evaluation of the efficacy of a novel electronic pain assessment device, the Pain Gauge, for measuring postoperative pain in rats. Lab Anim 2007, 41:46-54.
40. Brogden R.N., Heel R.C., Pakes G.E., Speight T.M., Avery G.S. Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin. Drugs 1980, 20:24-48.
41. Fleischmann R., Iqbal I., Slobodin G. Meloxicam. Expert Opin Pharmacother 2002, 3:1501-1512.
42. Luo R., Liu G., Liu W., Pei F., Zhou Z., Li J., et al. Efficacy of celecoxib, meloxicam and paracetamol in elderly Kashin-Beck disease (KBD) patients. Int Orthop 2011, 35:1409-1414.
43. Jean Y.H., Wen Z.H., Chang Y.C., Lee H.S., Hsieh S.P., Wu C.T., et al. Hyaluronic acid attenuates osteoarthritis development in the anterior cruciate ligament-transected knee: associated with excitatory amino acid release in the joint dialysate. JOrthop Res 2006, 24:1052-1061.
44. Hill C.L., Gale D.G., Chaisson C.E., Skinner K., Kazis L., Gale M.E., et al. Knee effusions, popliteal cysts, and synovial thickening: association with knee pain in osteoarthritis. JRheumatol 2001, 28:1330-1337.
45. Cross A.R., Budsberg S.C., Keefe T.J. Kinetic gait analysis assessment of meloxicam efficacy in a sodium urate-induced synovitis model in dogs. Am J Vet Res 1997, 58:626-631.
46. Castro R.R., Cunha F.Q., Silva F.S., Rocha F.A.C. Aquantitative approach to measure joint pain in experimental osteoarthritis-evidence of a role of nitric oxide. Osteoarthritis Cartilage 2006, 14:769-776.
47. Zheng W., Li R., Pan H., He D., Xu R., Guo T.B., et al. Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1 through the NF-kB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum 2009, 6(7):1957-1965.
48. Furestein G.S., Manning A.M. Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum 1999, 42:609-621.
49. Hucho T., Levine J.D. Signaling pathways in sensitization: toward a nociceptor cell biology. Neuron 2007, 55:365-376.
50. Lumpkin E.A., Caterina M.J. Mechanisms of sensory transduction in the skin. Nature 2007, 445:858-865.
51. Cruz C.D., Neto F.L., Castro-Lopes J., McMahon S.B., Cruz F. Inhibition of ERK phosphorylation decreases nociceptive behaviour in monoarthritic rats. Pain 2005, 116:411-419.